Epidermal growth factor reduces multiorgan failure induced by thioacetamide

Area of Science:

• Toxicology
• Regenerative Medicine
• Gastroenterology

Background:

• Multiorgan failure is a critical condition with limited therapeutic options.
• Epidermal growth factor (EGF) promotes tissue repair in experimental models.
• This study investigated EGF's protective effects against thioacetamide (TAA)-induced organ injury and mortality.

Purpose of the Study:

• To evaluate the efficacy of human recombinant EGF in preventing mortality and organ damage caused by TAA.
• To assess the impact of EGF administration timing (before or after TAA) on its protective effects.

Main Methods:

• Mice received intraperitoneal injections of EGF (10 or 30 microg/kg) or saline, followed by or preceded by TAA (40 mg/kg).
• Mortality was recorded within 24 hours.
• Organ injury (gastrointestinal, renal, hepatic) and plasma creatinine levels were assessed in surviving animals.

Main Results:

• EGF (30 microg/kg) almost completely prevented mortality, while the lower dose reduced it by 50%.
• EGF significantly reduced necrosis in the jejunum and ileum and mitigated renal injury, including glomerular collapse and increased creatinine.
• EGF did not prevent TAA-induced liver damage or elevated alanine transaminase levels.

Conclusions:

• Epidermal growth factor (EGF) demonstrates significant protective effects against TAA-induced mortality, gastrointestinal damage, and renal injury.
• EGF may represent a novel therapeutic strategy for preventing or treating multiorgan failure.
• Further research is warranted to explore EGF's clinical applicability in critical care settings.